Detail akcie Glaukos online

Business Summary: Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Glaukos Corp revenues increased 31% to $364.3M. Net loss decreased 52% to $54M. Revenues reflect Glaucoma segment increase of 38% to $301.9M, Corneal Health segment increase of 6% to $62.4M, United States segment increase of 37% to $267M, International segment increase of 17% to $97.3M. Lower net loss reflects Acquired in-process research and develop decrease from $14.2M (expense) to $0K.